X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

X4 Pharmaceuticals shares are described as technically oversold, suggesting heavy selling pressure may be exhausted. Wall Street analysts are broadly raising earnings estimates, which could support a potential reversal, though the outlook remains technical and speculative rather than based on reported operating results.